Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTX-2337 + pegylated liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- VentiRx
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
VTX-2337 + pegylated liposomal doxorubicin is a combination therapy under investigation for cancer treatment, notably ovarian cancer. **VTX-2337** is a small molecule Toll-like receptor 8 (TLR8) agonist designed to stimulate the innate immune system, enhance anti-tumor immune responses, and promote the production of pro-inflammatory cytokines[1][5]. **Pegylated liposomal doxorubicin** is a formulation of the anthracycline chemotherapy doxorubicin encapsulated in polyethylene glycol (PEG)-coated liposomes, which increases drug circulation time and preferentially delivers doxorubicin to tumor tissue, thereby maximizing anti-cancer efficacy while reducing systemic toxicity[2][4][6]. The combination aims to leverage the immune-modulating effects of VTX-2337 with the cytotoxic activity of pegylated liposomal doxorubicin for synergistic anti-tumor effects.
- Brand names
- Caelyx
02
Targets
TOP2A (DNA topoisomerase II)TLR8 (Toll-like receptor 8)DNATLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on VTX-2337 + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTX-2337 + pegylated liposomal doxorubicin.